Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Public ClinicalTrials.gov record NCT06744647. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Study identification
- NCT ID
- NCT06744647
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 47 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2025
- Primary completion
- Oct 10, 2027
- Completion
- Nov 6, 2028
- Last update posted
- Aug 10, 2026
2025 – 2028
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35249 | — |
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Atlanta | Georgia | 30309 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Livingston | New Jersey | 07039 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Durham | North Carolina | 27705 | — |
| Research Site | Cincinnati | Ohio | 45267 | — |
| Research Site | Philadelphia | Pennsylvania | 19140 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Richmond | Virginia | 23298 | — |
| Research Site | Seattle | Washington | 98195 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06744647, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06744647 live on ClinicalTrials.gov.